Open AccessDoes treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?
Author(s) -
Serdar Şahin,
Özlem Haliloğlu,
Özge Polat Korkmaz,
Emre Durcan,
Hümeyra Rekalı Şahin,
Volkan Yumuk,
Taner Damcı,
Hasan İlkova,
Zeynep Oşar Siva
Publication year - 2021
Publication title -
turkish journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.277
H-Index - 27
eISSN - 1303-6165
pISSN - 1300-0144
DOI - 10.3906/sag-2008-37
Subject(s) - medicine , pittsburgh sleep quality index , type 2 diabetes , diabetes mellitus , type 2 diabetes mellitus , quality of life (healthcare) , anxiety , body mass index , beck depression inventory , beck anxiety inventory , depression (economics) , physical therapy , vitality , sleep quality , psychiatry , endocrinology , insomnia , philosophy , nursing , macroeconomics , theology , economics
To evaluate the impact of treatment with sodium-glucose co-transporter-2 (SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ), and anxiety levels in patients with Type 2 diabetes mellitus (T2DM).